Cardio Metabolic Centre

The Cardio Metabolic Centre in Mattersburg is involved in clinical research focused on cardiovascular diseases, especially atherosclerotic cardiovascular disease and related heart-risk conditions. The studies are designed to test new treatment approaches that may reduce serious heart events and improve long-term outcomes for people at elevated cardiovascular risk.

• Research on atherosclerotic cardiovascular disease and ASCVD
• Studies targeting prevention of major cardiovascular events
• Evaluation of therapies aimed at lowering cardiovascular morbidity and mortality

These trials also examine conditions linked to heart disease, such as elevated Lp(a), with the goal of improving risk reduction and supporting better care for patients with complex cardiometabolic profiles.

Another major area of research at this site is nutritional and metabolic diseases, with a strong emphasis on obesity and overweight. The trials are exploring whether new therapies can help people living with excess weight while also lowering the chance of heart and kidney complications.

• Studies in obesity and overweight
• Research involving atherosclerotic cardiovascular disease with metabolic risk factors
• Testing treatments that may improve both weight-related and cardiovascular outcomes

By connecting metabolic health with heart protection, the Cardio Metabolic Centre is contributing to research that may support more effective care for people with overlapping weight and cardiovascular conditions.

Clinical trials at this health care site also address the link between heart disease and kidney health, including chronic kidney disease. In addition, the centre is studying elevated lipoprotein(a), a factor associated with increased cardiovascular risk, to better understand how emerging therapies may reduce future complications.

• Research on the relationship between cardiovascular disease and kidney outcomes
• Trials in chronic kidney disease alongside heart-risk conditions
• Evaluation of treatments for elevated Lp(a) to reduce major cardiac events

This mix of cardiorenal and lipid-focused studies reflects a broader effort to improve prevention and treatment for patients with interconnected metabolic and cardiovascular disorders.